A woman on dulaglutide for 16 months developed markedly elevated CA19-9 and CA242 tumor markers that normalized within 6 weeks of stopping the drug, with no underlying cancer found.
6 weeks to normalizationCA19-9 and CA242 levels returned to normal after discontinuing dulaglutide, with no cancer found
What the researchers found
Dulaglutide caused significant elevation of serum CA19-9 and CA242 levels in an asymptomatic patient, which completely normalized within 6 weeks of drug discontinuation.
Why it matters
As GLP-1 drugs become increasingly common, clinicians will encounter more patients with unexplained elevated tumor markers. Knowing that dulaglutide can cause this effect could prevent unnecessary invasive procedures, reduce patient anxiety, and save healthcare resources.
The numbers in context
Mid-60s female, dulaglutide for 16 months. Elevated CA19-9 and CA242 resolved after stopping.
How the study worked
Single case report with clinical workup including imaging and interventional assessments to exclude malignancy, followed by dulaglutide discontinuation and marker monitoring.
Who was studied
Mid-60s female with T2DM on dulaglutide for 16 months
What this study cannot tell us
Single case report — cannot determine how common this effect is. The mechanism by which dulaglutide elevates these markers was not investigated. It's unclear whether other GLP-1 drugs cause similar marker elevations.
How to read the evidence
Preliminary evidence from a single case report. Demonstrates a clear temporal association but cannot establish how common this effect is.
When this study was published
Published in 2024. Relevant as GLP-1 drug prescriptions continue to surge worldwide.
The bigger picture
This case adds to growing awareness of unexpected effects from GLP-1 receptor agonists. As these drugs are prescribed to millions, rare adverse effects and drug-biomarker interactions become increasingly important for clinical practice. Cancer screening protocols may need to account for GLP-1 drug use.
Questions still open
- Do other GLP-1 receptor agonists (semaglutide, liraglutide) similarly elevate CA19-9 and CA242?
- What is the mechanism by which dulaglutide causes tumor marker elevation?
- Should patients on GLP-1 drugs receive modified cancer screening protocols?
Common questions
What are CA19-9 and CA242, and why are elevated levels concerning?
Should I stop taking dulaglutide if I have elevated tumor markers?
Read the original research
Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.
BMJ case reports, 17(5)
Citation
Shi, Xiaomin. (2024). Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.. BMJ case reports, 17(5). https://doi.org/10.1136/bcr-2023-257657